Testing the safety of avelumab and axitinib on patients with kidney cancer (JAVELIN Renal 100)
A Phase 1b, Open-Label, Dose-Finding Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of Avelumab (MSB0010718C) in Combination With Axitinib (AG-013736) in Patients With Previously Untreated Advanced Renal Cell Cancer
Category & Conditions: Cancer
Medicine: Bavencio (avelumab)
INLYTA®(AXITINIB)
ClinicalTrials.gov Identifier (NCT): NCT02493751
Protocol ID: B9991002
PrintDownloadOpen Plain Language Summary Result: Click here